Healthcare
By
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring Orna Therapeutics to Revolutionize Autoimmune Treatments
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology, rare diseases, vaccines,…
